{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:46:36Z","timestamp":1782733596793,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Psychische Erkrankungen treten bei Menschen mit Epilepsie h\u00e4ufiger auf, umgekehrt haben psychiatrische Patient*innen ein erh\u00f6htes Epilepsierisiko. Psychosoziale Faktoren, Medikamenteneffekte, peri- und interiktale Symptome spielen ebenso wie gemeinsame genetische Mechanismen eine Rolle, insbesondere bei seltenen monogenetischen Epilepsiesyndromen. Der \u00dcbersichtsartikel behandelt exemplarisch\n                    <jats:italic>GRIN2A<\/jats:italic>\n                    -assoziierte Syndrome, entwicklungsbedingte und epileptische Enzephalopathien einschlie\u00dflich Dravet-Syndrom sowie tuber\u00f6se Sklerose. Zusammengefasst werden neuropsychiatrische Manifestationen, pathophysiologische Grundlagen und zielgerichtete Therapien. Schwerpunkt ist die systematische Erfassung psychiatrischer Symptome und die pr\u00e4zise klinische Ph\u00e4notypisierung zur Beurteilung krankheitsmodifizierender Therapieeffekte jenseits der Anfallskontrolle. Ziel ist es, klinische Implikationen, Versorgungsdefizite und offene Fragen aufzuzeigen und interdisziplin\u00e4re neurologisch-psychiatrische Betreuung zu f\u00f6rdern.\n                  <\/jats:p>","DOI":"10.1007\/s00115-026-01982-3","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:30:49Z","timestamp":1780050649000},"page":"345-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zusammenh\u00e4nge zwischen genetischen Ursachen psychischer Erkrankungen und seltenen monogenetischen Epilepsien","Associations Between Genetic Causes of Psychiatric Disorders and Rare Monogenic Epilepsies"],"prefix":"10.1007","volume":"97","author":[{"given":"Caroline","family":"Baumgartner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Philipsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Surges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"4","key":"1982_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.biopsych.2006.09.023","volume":"62","author":"K Alper","year":"2007","unstructured":"Alper\u00a0K, Schwartz\u00a0KA, Kolts\u00a0RL, Khan\u00a0A (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 62(4):345\u2013354. https:\/\/doi.org\/10.1016\/j.biopsych.2006.09.023","journal-title":"Biol Psychiatry"},{"issue":"6","key":"1982_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5006","volume":"11","author":"A Anwar","year":"2019","unstructured":"Anwar\u00a0A, Saleem\u00a0S, Patel\u00a0UK, Arumaithurai\u00a0K, Malik\u00a0P (2019) Dravet Syndrome: An Overview. Cureus 11(6):e5006. https:\/\/doi.org\/10.7759\/cureus.5006","journal-title":"Cureus"},{"issue":"5","key":"1982_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.neurol.2025.04.003","volume":"181","author":"S Auvin","year":"2025","unstructured":"Auvin\u00a0S (2025) Targeted therapies in epilepsies. Rev Neurol (Paris) 181(5):450\u2013455. https:\/\/doi.org\/10.1016\/j.neurol.2025.04.003","journal-title":"Rev Neurol (Paris)"},{"key":"1982_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2022.108994","volume":"138","author":"KI Bishop","year":"2023","unstructured":"Bishop\u00a0KI, Isquith\u00a0PK, Gioia\u00a0GA et\u00a0al (2023) Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (\u3008\u202f5\u00a0years) with Dravet syndrome: A\u00a0critical period for early neurodevelopment. Epilepsy Behav 138:108994. https:\/\/doi.org\/10.1016\/j.yebeh.2022.108994","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1982_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.11.012","volume":"25","author":"E Boot","year":"2023","unstructured":"Boot\u00a0E, \u00d3skarsd\u00f3ttir\u00a0S, Loo\u00a0JCY et\u00a0al (2023) Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome. Genet Med 25(3):100344. https:\/\/doi.org\/10.1016\/j.gim.2022.11.012","journal-title":"Genet Med"},{"key":"1982_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106669","volume":"102","author":"C Campbell","year":"2020","unstructured":"Campbell\u00a0C, Cavalleri\u00a0GL, Delanty\u00a0N (2020) Exploring the genetic overlap between psychiatric illness and epilepsy: A review. Epilepsy Behav 102:106669. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106669","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1982_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/epi4.12569","volume":"7","author":"E Cardenal-Mu\u00f1oz","year":"2022","unstructured":"Cardenal-Mu\u00f1oz\u00a0E, Auvin\u00a0S, Villanueva\u00a0V et\u00a0al (2022) Guidance on Dravet syndrome from infant to adult care: Road map for treatment planning in Europe. Epilepsia Open 7(1):11\u201326. https:\/\/doi.org\/10.1002\/epi4.12569","journal-title":"Epilepsia Open"},{"issue":"3","key":"1982_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030783","volume":"11","author":"TS Chen","year":"2023","unstructured":"Chen\u00a0TS, Huang\u00a0TH, Lai\u00a0MC, Huang\u00a0CW (2023) The Role of Glutamate Receptors in Epilepsy. Biomedicines 11(3):783. https:\/\/doi.org\/10.3390\/biomedicines11030783","journal-title":"Biomedicines"},{"issue":"1-3","key":"1982_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.schres.2014.12.026","volume":"167","author":"SM Cohen","year":"2015","unstructured":"Cohen\u00a0SM, Tsien\u00a0RW, Goff\u00a0DC, Halassa\u00a0MM (2015) The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia. Schizophr Res 167(1-3):98\u2013107. https:\/\/doi.org\/10.1016\/j.schres.2014.12.026","journal-title":"Schizophr Res"},{"issue":"9","key":"1982_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/dtb.2019.000044","volume":"58","author":"DP Craig","year":"2020","unstructured":"Craig\u00a0DP, Osborne\u00a0C (2020) Risk of seizures with antidepressants: what is the evidence? Drug Ther Bull 58(9):137\u2013140. https:\/\/doi.org\/10.1136\/dtb.2019.000044","journal-title":"Drug Ther Bull"},{"issue":"4","key":"1982_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.neurol.2023.12.005","volume":"180","author":"B de Toffol","year":"2024","unstructured":"de Toffol\u00a0B (2024) Epilepsy and psychosis. Rev Neurol (Paris) 180(4):298\u2013307. https:\/\/doi.org\/10.1016\/j.neurol.2023.12.005","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"1982_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-023-09500-1","volume":"15","author":"PJ de Vries","year":"2023","unstructured":"de Vries\u00a0PJ, Heunis\u00a0TM, Vanclooster\u00a0S et\u00a0al (2023) International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). J\u00a0Neurodev Disord 15(1):32. https:\/\/doi.org\/10.1186\/s11689-023-09500-1","journal-title":"J Neurodev Disord"},{"issue":"Suppl 2","key":"1982_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","volume":"52","author":"C Dravet","year":"2011","unstructured":"Dravet\u00a0C (2011) The core Dravet syndrome phenotype. Epilepsia 52(Suppl 2):3\u20139. https:\/\/doi.org\/10.1111\/j.1528-1167.2011.02994.x","journal-title":"Epilepsia"},{"issue":"1","key":"1982_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03495-1","volume":"20","author":"JH Driedger","year":"2025","unstructured":"Driedger\u00a0JH, Schr\u00f6ter\u00a0J, PROTECT-Study Group, Syrbe\u00a0S, Saffari\u00a0A (2025) Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4\u00a0months of age (PROTECT), a\u00a0two-arm, randomized, observer-blind, controlled phase\u00a0IIb national multicentre clinical trial: study protocol. Orphanet J Rare Dis 20(1):2. https:\/\/doi.org\/10.1186\/s13023-024-03495-1","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1982_CR15","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/s41593-024-01747-8","volume":"27","author":"Epi25 Collaborative","year":"2024","unstructured":"Epi25 Collaborative (2024) Exome sequencing of 20,979 individuals with epilepsy reveals shared and distinct ultra-rare genetic risk across disorder subtypes. Nat Neurosci 27(10):1864\u20131879. https:\/\/doi.org\/10.1038\/s41593-024-01747-8","journal-title":"Nat Neurosci"},{"key":"1982_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.seizure.2016.10.014","volume":"44","author":"S Gataullina","year":"2017","unstructured":"Gataullina\u00a0S, Dulac\u00a0O (2017) From genotype to phenotype in Dravet disease. Seizure 44:58\u201364. https:\/\/doi.org\/10.1016\/j.seizure.2016.10.014","journal-title":"Seizure"},{"key":"1982_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109958","volume":"158","author":"S Giorgi","year":"2024","unstructured":"Giorgi\u00a0S, Auvin\u00a0S, Schoonjans\u00a0AS et\u00a0al (2024) A tool for Dravet syndrome-associated neuropsychiatric comorbidities evaluation (DANCE). Epilepsy Behav 158:109958. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109958","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1982_CR18","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/epi.16833","volume":"62","author":"J Harowitz","year":"2021","unstructured":"Harowitz\u00a0J, Crandall\u00a0L, McGuone\u00a0D, Devinsky\u00a0O (2021) Seizure-related deaths in children: The expanding spectrum. Epilepsia 62(3):570\u2013582. https:\/\/doi.org\/10.1111\/epi.16833","journal-title":"Epilepsia"},{"key":"1982_CR19","unstructured":"Holtkamp M, May TW, Berkenfeld R, Bien CG, Coban I, Knake S, Michaelis R, R\u00e9mi J, Seeck M, Surges R, Weber YDeutsche Gesellschaft f\u00fcr Neurologie et\u00a0al (Hrsg) (2023) Erster epileptischer Anfall und Epilepsien im Erwachsenenalter, S2k-Leitlinie, 2023; in: Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien. Zugegriffen: 28. Jan. 2026"},{"issue":"1","key":"1982_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98517-4","volume":"11","author":"CH Huang","year":"2021","unstructured":"Huang\u00a0CH, Hung\u00a0PL, Fan\u00a0PC et\u00a0al (2021) Clinical spectrum and the comorbidities of Dravet syndrome in Taiwan and the possible molecular mechanisms. Sci Rep 11(1):20242. https:\/\/doi.org\/10.1038\/s41598-021-98517-4","journal-title":"Sci Rep"},{"key":"1982_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106976","volume":"185","author":"MP Jensen","year":"2022","unstructured":"Jensen\u00a0MP, Gammaitoni\u00a0AR, Galer\u00a0BS, Salem\u00a0R, Wilkie\u00a0D, Amtmann\u00a0D (2022) Fenfluramine treatment for dravet syndrome: Real-world benefits on quality of life from the caregiver perspective. Epilepsy Res 185:106976. https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.106976","journal-title":"Epilepsy Res"},{"issue":"8","key":"1982_CR22","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1093\/brain\/awad038","volume":"146","author":"N Karadag","year":"2023","unstructured":"Karadag\u00a0N, Shadrin\u00a0AA, O\u2019Connell\u00a0KS et\u00a0al (2023) Identification of novel genomic risk loci shared between common epilepsies and psychiatric disorders. Brain 146(8):3392\u20133403. https:\/\/doi.org\/10.1093\/brain\/awad038","journal-title":"Brain"},{"issue":"4","key":"1982_CR23","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00115-024-01737-y","volume":"96","author":"LL Kilarski","year":"2025","unstructured":"Kilarski\u00a0LL, Claus\u00a0I, Binder\u00a0EB et\u00a0al (2025) Genetische Diagnostik bei psychischen Erkrankungen im Erwachsenenalter [Genetic diagnostics of mental health disorders in adulthood]. Nervenarzt 96(4):386\u2013395. https:\/\/doi.org\/10.1007\/s00115-024-01737-y","journal-title":"Nervenarzt"},{"key":"1982_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109203","volume":"218","author":"M Koike-Kumagai","year":"2022","unstructured":"Koike-Kumagai\u00a0M, Fujimoto\u00a0M, Wataya-Kaneda\u00a0M (2022) Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice. Neuropharmacology 218:109203. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109203","journal-title":"Neuropharmacology"},{"issue":"12","key":"1982_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/acn3.494","volume":"4","author":"DA Krueger","year":"2017","unstructured":"Krueger\u00a0DA, Sadhwani\u00a0A, Byars\u00a0AW et\u00a0al (2017) Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. Ann Clin Transl Neurol 4(12):877\u2013887. https:\/\/doi.org\/10.1002\/acn3.494","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"1982_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ana.23960","volume":"74","author":"DA Krueger","year":"2013","unstructured":"Krueger\u00a0DA, Wilfong\u00a0AA, Holland-Bouley\u00a0K et\u00a0al (2013) Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 74(5):679\u2013687. https:\/\/doi.org\/10.1002\/ana.23960","journal-title":"Ann Neurol"},{"issue":"1","key":"1982_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jamaneurol.2024.3976","volume":"82","author":"CS Kwon","year":"2025","unstructured":"Kwon\u00a0CS, Rafati\u00a0A, Ottman\u00a0R, Christensen\u00a0J, Kanner\u00a0AM, Jett\u00e9\u00a0N, Newton\u00a0CR (2025) Psychiatric Comorbidities in Persons With Epilepsy Compared With Persons Without Epilepsy: A Systematic Review and Meta-Analysis. JAMA Neurol 82(1):72\u201384. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3976","journal-title":"JAMA Neurol"},{"issue":"10216","key":"1982_CR28","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","volume":"394","author":"L Lagae","year":"2019","unstructured":"Lagae\u00a0L, Sullivan\u00a0J, Knupp\u00a0K et\u00a0al (2019) Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 394(10216):2243\u20132254. https:\/\/doi.org\/10.1016\/S0140-6736(19)32500-0","journal-title":"Lancet"},{"key":"1982_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-03279-4","author":"JR Lemke","year":"2025","unstructured":"Lemke\u00a0JR, Eoli\u00a0A, Krey\u00a0I et\u00a0al (2025) GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-025-03279-4","journal-title":"Mol Psychiatry"},{"key":"1982_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02266-0","volume":"17","author":"C Luo","year":"2022","unstructured":"Luo\u00a0C, Ye\u00a0WR, Shi\u00a0W et\u00a0al (2022) Perfect match: mTOR inhibitors and tuberous sclerosis complex. Orphanet J Rare Dis 17:106. https:\/\/doi.org\/10.1186\/s13023-022-02266-0","journal-title":"Orphanet J Rare Dis"},{"key":"1982_CR31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.seizure.2021.11.021","volume":"94","author":"R Mayor","year":"2022","unstructured":"Mayor\u00a0R, Gunn\u00a0S, Reuber\u00a0M, Simpson\u00a0J (2022) Experiences of stigma in people with epilepsy: A meta-synthesis of qualitative evidence. Seizure 94:142\u2013160. https:\/\/doi.org\/10.1016\/j.seizure.2021.11.021","journal-title":"Seizure"},{"issue":"1","key":"1982_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.braindev.2018.07.003","volume":"41","author":"M Mizuguchi","year":"2019","unstructured":"Mizuguchi\u00a0M, Ikeda\u00a0H, Kagitani-Shimono\u00a0K et\u00a0al (2019) Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST\u20113 substudy in Japan. Brain Dev 41(1):1\u201310. https:\/\/doi.org\/10.1016\/j.braindev.2018.07.003","journal-title":"Brain Dev"},{"issue":"3","key":"1982_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/epi4.12414","volume":"5","author":"J Klepper","year":"2020","unstructured":"Klepper\u00a0J, Akman\u00a0C, Armeno\u00a0M et\u00a0al (2020) Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open 5(3):354\u2013365. https:\/\/doi.org\/10.1002\/epi4.12414","journal-title":"Epilepsia Open"},{"key":"1982_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"H Northrup","year":"2021","unstructured":"Northrup\u00a0H, Aronow\u00a0ME, Bebin\u00a0EM et\u00a0al (2021) Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol 123:50\u201366. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.07.011","journal-title":"Pediatr Neurol"},{"issue":"5","key":"1982_CR35","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/epi.17547","volume":"64","author":"KL Oliver","year":"2023","unstructured":"Oliver\u00a0KL, Scheffer\u00a0IE, Bennett\u00a0MF, Grinton\u00a0BE, Bahlo\u00a0M, Berkovic\u00a0SF (2023) Genes4Epilepsy: An epilepsy gene resource. Epilepsia 64(5):1368\u20131375. https:\/\/doi.org\/10.1111\/epi.17547","journal-title":"Epilepsia"},{"key":"1982_CR36","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/TCRM.S145630","volume":"15","author":"IE Overwater","year":"2019","unstructured":"Overwater\u00a0IE, Rietman\u00a0AB, van Eeghen\u00a0AM, de Wit\u00a0MCY (2019) Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives. Ther Clin Risk Manag 15:951\u2013955. https:\/\/doi.org\/10.2147\/TCRM.S145630","journal-title":"Ther Clin Risk Manag"},{"issue":"13","key":"1982_CR37","doi-asserted-by":"publisher","first-page":"e1770","DOI":"10.1212\/WNL.0000000000011655","volume":"96","author":"EE Palmer","year":"2021","unstructured":"Palmer\u00a0EE, Sachdev\u00a0R, Macintosh\u00a0R et\u00a0al (2021) Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies. Neurology 96(13):e1770\u2013e1782. https:\/\/doi.org\/10.1212\/WNL.0000000000011655","journal-title":"Neurology"},{"issue":"13","key":"1982_CR38","doi-asserted-by":"publisher","first-page":"e1363","DOI":"10.1212\/WNL.0000000000206758","volume":"100","author":"G Poke","year":"2023","unstructured":"Poke\u00a0G, Stanley\u00a0J, Scheffer\u00a0IE, Sadleir\u00a0LG (2023) Epidemiology of Developmental and Epileptic Encephalopathy and of Intellectual Disability and Epilepsy in Children. Neurology 100(13):e1363\u2013e1375. https:\/\/doi.org\/10.1212\/WNL.0000000000206758","journal-title":"Neurology"},{"issue":"3","key":"1982_CR39","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/epi.14678","volume":"60","author":"DRM Vlaskamp","year":"2019","unstructured":"Vlaskamp\u00a0DRM, Bassett\u00a0AS, Sullivan\u00a0JE et\u00a0al (2019) Schizophrenia is a\u00a0later-onset feature of PCDH19 Girls Clustering Epilepsy. Epilepsia 60(3):429\u2013440. https:\/\/doi.org\/10.1111\/epi.14678","journal-title":"Epilepsia"},{"issue":"2","key":"1982_CR40","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/WCO.0000000000001141","volume":"36","author":"SM Ruggiero","year":"2023","unstructured":"Ruggiero\u00a0SM, Xian\u00a0J, Helbig\u00a0I (2023) The current landscape of epilepsy genetics: where are we, and where are we going? Curr Opin Neurol 36(2):86\u201394. https:\/\/doi.org\/10.1097\/WCO.0000000000001141","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"1982_CR41","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/epi.18265","volume":"66","author":"IE Scheffer","year":"2025","unstructured":"Scheffer\u00a0IE, French\u00a0J, Valente\u00a0KD, Auvin\u00a0S, Cross\u00a0JH, Specchio\u00a0N (2025) Operational definition of developmental and epileptic encephalopathies to underpin the design of therapeutic trials. Epilepsia 66(4):1014\u20131023. https:\/\/doi.org\/10.1111\/epi.18265","journal-title":"Epilepsia"},{"issue":"6","key":"1982_CR42","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/epi.18329","volume":"66","author":"A Selvarajah","year":"2025","unstructured":"Selvarajah\u00a0A, Sabo\u00a0A, Gorodetsky\u00a0C et\u00a0al (2025) Dravet syndrome: From neurodevelopmental to neurodegenerative disease? Epilepsia 66(6):1975\u20131987. https:\/\/doi.org\/10.1111\/epi.18329","journal-title":"Epilepsia"},{"issue":"1","key":"1982_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53102-3","volume":"14","author":"N Shepard","year":"2024","unstructured":"Shepard\u00a0N, Baez-Nieto\u00a0D, Iqbal\u00a0S, Kurganov\u00a0E et\u00a0al (2024) Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders. Sci Rep 14(1):2798. https:\/\/doi.org\/10.1038\/s41598-024-53102-3","journal-title":"Sci Rep"},{"issue":"7906","key":"1982_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-022-04556-w","volume":"604","author":"T Singh","year":"2022","unstructured":"Singh\u00a0T, Poterba\u00a0T, Curtis\u00a0D et\u00a0al (2022) Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature 604(7906):509\u2013516. https:\/\/doi.org\/10.1038\/s41586-022-04556-w","journal-title":"Nature"},{"issue":"1","key":"1982_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/epi.17115","volume":"63","author":"N Specchio","year":"2022","unstructured":"Specchio\u00a0N, Di Micco\u00a0V, Trivisano\u00a0M, Ferretti\u00a0A, Curatolo\u00a0P (2022) The epilepsy-autism spectrum disorder phenotype in the era of molecular genetics and precision therapy. Epilepsia 63(1):6\u201321. https:\/\/doi.org\/10.1111\/epi.17115","journal-title":"Epilepsia"},{"key":"1982_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00639","volume":"11","author":"N Specchio","year":"2020","unstructured":"Specchio\u00a0N, Pietrafusa\u00a0N, Trivisano\u00a0M et\u00a0al (2020) Autism and Epilepsy in Patients With Tuberous Sclerosis Complex. Front Neurol 11:639. https:\/\/doi.org\/10.3389\/fneur.2020.00639","journal-title":"Front Neurol"},{"issue":"11","key":"1982_CR47","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S2352-4642(24)00196-2","volume":"8","author":"N Specchio","year":"2024","unstructured":"Specchio\u00a0N, Trivisano\u00a0M, Aronica\u00a0E et\u00a0al (2024) The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. Lancet Child Adolesc Health 8(11):821\u2013834. https:\/\/doi.org\/10.1016\/S2352-4642(24)00196-2","journal-title":"Lancet Child Adolesc Health"},{"key":"1982_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107939","volume":"118","author":"BJ Steinhoff","year":"2021","unstructured":"Steinhoff\u00a0BJ, Klein\u00a0P, Klitgaard\u00a0H et\u00a0al (2021) Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A\u00a0systematic review. Epilepsy Behav 118:107939. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107939","journal-title":"Epilepsy Behav"},{"key":"1982_CR49","doi-asserted-by":"publisher","unstructured":"Strehlow V, Heyne HO, Vlaskamp DRM, et\u00a0al. (2019) GRIN2A-related disorders: genotype and functional consequence predict phenotype. Brain. 142(1):80\u201392 https:\/\/doi.org\/10.1093\/brain\/awy304","DOI":"10.1093\/brain\/awy304"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-01982-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01982-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:19:25Z","timestamp":1782731965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-01982-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-01982-3","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Baumgartner, T.\u00a0Baumgartner und E.C.\u00a0Schulte geben an, dass kein Interessenkonflikt besteht. A.\u00a0Philipsen war im vergangenen Jahr als Beraterin f\u00fcr Boehringer, Medice Health Family und Takeda t\u00e4tig, hat dabei im Bereich ADHS bei der Entwicklung, wissenschaftlichen Evaluation, Publikation von ORIKO mitgewirkt und war bei der Evaluation und Publikation der Ergebnisse von Attexis beteiligt. R.\u00a0Surges hat in den letzten 3\u00a0Jahren Honorare f\u00fcr Vortr\u00e4ge oder als Berater von Angelini, Desitin, Eisai, Jazz Pharmaceuticals Germany GmbH, Janssen-Cilag GmbH, LivaNova, LivAssured B.V., Novartis, Precisis GmbH, Rapport Therapeutics, Tabuk Pharmaceuticals, UCB Pharma, UNEEG erhalten. Diese T\u00e4tigkeiten stehen in keinem direkten Zusammenhang mit den Inhalten dieser Publikation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}